SK Biopharm held a sales meeting with its employees in the U.S. &#40;Provided by SK Biopharm&#41; / News1

SK Biopharm announced that its U.S. subsidiary, SK Life Science, recently held its 2026 National Sales Meeting in Orlando, Florida.

This annual event, now in its seventh year, has been a tradition since the 2020 launch of the epilepsy medication Cenobamate (marketed as Xcopri in the U.S.). The gathering drew over 290 employees from both domestic and international teams, including Chief Executive Officer (CEO) Lee Dong-hoon.

The meeting brought together all members of the local subsidiary to reflect on the past year's achievements and strategize for future sales growth. This year's slogan, We Will, underscores the company's commitment to fostering proactive engagement and personal development among team members.

Central to the meeting was the One Team synergy strategy, which aims to leverage the combined expertise of both headquarters and the U.S. subsidiary across research and development, strategy, and marketing.

The two entities are aligning their efforts under a unified direction and set of priorities to bolster the Cenobamate business and expand into the oncology sector.

SK Biopharm intends to enhance cross-organizational collaboration and boost operational efficiency. The company reinforced its grasp of cutting-edge marketing trends and field expertise through a series of lectures featuring patients and healthcare professionals, complemented by sales team-led workshops.

Cenobamate hit a milestone in the U.S. market last year, with sales soaring to approximately 630.3 billion KRW (about 436 million USD), marking a 44% increase from the previous year. Looking ahead, SK Biopharm and SK Life Science aim to accelerate their ascent to global blockbuster status by implementing targeted marketing strategies and expanding their prescription market share.

CEO Lee emphasized that the core of its One Team strategy lies in dismantling organizational silos and moving forward with shared goals and priorities. They're leveraging Cenobamate's success as a springboard for business expansion, cultivating an environment where every team member plays an active role in shaping the future.

SK Biopharm announced that its U.S. subsidiary, SK Life Science, recently held its 2026 Na …

SK Biopharm's 2026 Sales Meeting: Key Strategies for Cenobamate's Global Success